| Financial Summary | | PTS,
Inc.
is
engaged
in
the
development
of
two
separate
diagnostic
tools:
its
allergy
testing
device
and
its
chiropractic
outcome-measuring
instrument.
The
Company's
primary
product,
the
ELASAT
Device,
is
designed
to
accurately
diagnose
allergies.
For
the
three
months
ended
3/01,
the
Company
reported
no
revenues.
Net
loss
fell
22%
to
$651
thousand.
Results
reflect
limited
operations
and
the
focus
on
the
development
of
an
allergy-testing
device. | More
from
Market Guide: Significant
Developments |
| Officers | | Phillip
Flaherty,
Pres. Thomas
F. Krucker,
CEO/Secy. Brian
Loke,
Treas. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|